<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862302</url>
  </required_header>
  <id_info>
    <org_study_id>HALPCARD-2013</org_study_id>
    <nct_id>NCT01862302</nct_id>
  </id_info>
  <brief_title>Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium</brief_title>
  <acronym>HALPCARD</acronym>
  <official_title>Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium: A Randomized Placebo-Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Will the use of prophylactic Haloperidol for patients undergoing open heart surgery reduce
      the incidence, duration, and severity of post cardiotomy delirium?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot study for feasibility and safety, n = 40, haloperidol 1mg vs. placebo BID administered
      night before and day of surgery, then continued for total 72hrs post-op, if delirium occurs
      study drug is stopped and usual standard of care implemented by MRP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of conducting a trial utilizing low dose Haloperidol use in patients post cardiac surgery</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days.</time_frame>
    <description>If a participant does not develop delirium post operatively, then the confusion assessment method (CAM)will be monitored for 24 hours after the study medication ends. Patients will be followed up until seven days or until discharge if no delirium occurs, or if delirium is detected, up to 30 days or until discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety monitoring of low dose Haloperidol use in patients post cardiac surgery</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
    <description>If a participant does not develop delirium post operatively, then the confusion assessment method (CAM)will be monitored for 24 hours after the study medication ends. Patients will be followed up until seven days or until discharge if no delirium occurs, or if delirium is detected, up to 30 days or until discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of delirium</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium severity</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of stay (LOS), with breakdown for intensive care unit (ICU) days and ward days</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of delirium</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>An economic analysis will be completed to determine if Haloperidol prophylaxis resulted in any cost savings</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Postoperative Confusion</condition>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery</description>
    <arm_group_label>Haloperidol</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to 70 years of age, undergoing a median sternotomy OR 60-69yrs
             of age with one or more of the risk factors:

               -  TIA/Stroke;

               -  Euroscore greater than or equal to 5;

               -  abnormal clock draw.

        Exclusion Criteria:

          -  Parkinsonism,

          -  on any antipsychotic medications pre-op,

          -  active delirium,

          -  emergent surgery,

          -  Haloperidol allergy,

          -  schizophrenia,

          -  prolonged QTc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Lamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton General Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2013</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Andre Lamy</investigator_full_name>
    <investigator_title>Dr Andre Lamy, MD, FRCSC, MHSc, Cardiac Surgeon</investigator_title>
  </responsible_party>
  <keyword>Prevention delirium</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Confusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

